Skip to main
PVLA
PVLA logo

PVLA Stock Forecast & Price Target

PVLA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palvella Therapeutics Inc is advancing its lead product candidate, QTORIN rapamycin, which has demonstrated statistically significant improvements in clinical signs related to rare genetic skin diseases during its Phase 2 trial, showing strong potential for enhancing patient quality of life. The upcoming Phase 3 SELVA trial will further assess the product's efficacy and safety, with expectations of positive results similar to the previous trial, highlighting its well-tolerated profile and low systemic absorption of the drug. Moreover, the QTORIN platform is positioned for broad expansion opportunities across various rare diseases, which may bolster its market potential and establish QTORIN as a leading treatment option in this therapeutic area.

Bears say

Palvella Therapeutics faces significant challenges as its lead product candidate, QTORIN rapamycin, is positioned in a market with high unmet medical needs due to the serious burden of the diseases it aims to treat. Despite the clinical development of QTORIN rapamycin for rare genetic skin disorders, the existing treatment options for patients are described as less than ideal, indicating a potential market hesitation. Additionally, the problems associated with these conditions, including severe pain and the risk of serious infections, could hinder patient adoption and long-term commercial success of the product.

PVLA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palvella Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palvella Therapeutics Inc (PVLA) Forecast

Analysts have given PVLA a Strong Buy based on their latest research and market trends.

According to 8 analysts, PVLA has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.